Hair loss & androgenic alopecia

What changes during this transition

Hair loss is a domain where peptide community claims and clinical reality have an unusually wide gap. The dominant interventions for androgenic alopecia — the most common type, covering male-pattern frontal-and-vertex thinning and female-pattern diffuse thinning — have decades of RCT data and clear standard-of-care positioning. Finasteride 1 mg orally (FDA-approved for AGA since 1997) maintains or improves hair in roughly 80% of users and produces measurable regrowth in around 40%. Topical minoxidil 5% (FDA-OTC since 1996) extends anagen and works via vasodilation plus K-channel opening. Oral low-dose minoxidil (2.5-5 mg, off-label, popularized by Rodney Sinclair's dermatology protocols since around 2020) has exploded in use with reasonable cardiac monitoring. Dutasteride 0.5 mg is more potent than finasteride and approved as an AGA indication in Korea and Japan, off-label in the US. LLLT devices are FDA-cleared. PRP has heterogeneous protocols and mixed but real evidence. Hair transplant (FUE/FUT) is the structural intervention. Spironolactone covers female-pattern as anti-androgen. This is the conversation, and any honest peptide framing has to sit underneath it. GHK-Cu is the one peptide that earns a discovery card here, and the honest framing is 'topical adjunct with mechanistic rationale and small-trial support' — not a substitute for finasteride or minoxidil. The Pickart-group copper-peptide work spans 30+ years, Pyo 2007 showed measurable hair-density increase in a split-scalp male AGA study, and the cosmetic OTC market reflects broad use as adjunct. What GHK-Cu isn't: a monotherapy with Phase 3 data, a head-to-head competitor with finasteride, or a validated intradermal scalp-injection protocol (the topical route has the evidence; injection is thinner). Use it as a layer on top of standard-of-care if you want — don't use it instead of standard-of-care. What's NOT surfaced as discovery here is editorially load-bearing. CJC-1295's 'GH-axis treats hair loss' framing is community-stack marketing with zero human AGA trial support. BPC-157 has no published human hair-loss outcome data — the wellness-clinic stacks bundling it into hair-restoration protocols are extending the broader healing-context literature beyond what's been tested. TB-500 has a defensible mouse-follicle preclinical signal (Philp 2004) but zero human AGA trial, plus an independent WADA-prohibited sanction risk for any athlete. These three are substrate-only — they exist in /ask for honest answers when users encounter the claims, not as discovery cards that would suggest the peptides belong in a hair-loss protocol. Semaglutide is the other substrate-only entry, and it's here for a different reason: the GLP-1 cohorts in STEP and SELECT show 3-7% hair-loss adverse-event reporting, the mechanism is rapid-weight-loss telogen effluvium rather than direct follicle damage, and users who shed 2-4 months in often blame the peptide and stop — forfeiting the cardiovascular and metabolic benefits that are the point. The honest answer is that the shedding is transient, the timeline runs 6-12 months from weight plateau, and protein-intake plus ferritin plus TSH optimization addresses the fixable contributors.